The Claim
In hypertensive patients with fasting glucose levels ≤125 mg/dL, the triglyceride-glucose (TyG) index is not associated with cholesterol efflux capacity (CEC), indicating that HDL functionality remains unchanged during early metabolic dysfunction prior to microvascular impairment.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with high blood pressure and normal fasting blood sugar, the triglyceride-glucose index does not relate to how well HDL cholesterol removes fat from cells, suggesting HDL function is not impaired at this early stage of metabolic change.
See the scientific wording
In hypertensive patients with fasting glucose levels ≤125 mg/dL, the triglyceride-glucose (TyG) index is not associated with cholesterol efflux capacity (CEC), suggesting that HDL functionality may remain intact during early metabolic dysfunction before microvascular impairment becomes evident.
When insulin resistance increases, the body produces fewer cells that repair tiny blood vessels, causing those vessels to function poorly. At the same time, the ability of HDL cholesterol to remove fat from cells stays unchanged, even though other signs of metabolic stress are present.
What the research says
1 studyIn people with high blood pressure and slightly high blood sugar, a marker of insulin resistance (TyG) didn’t affect how well HDL cholesterol removes fat from cells—even though their tiny blood vessels were already showing signs of trouble. This means HDL might still be working fine early on.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.